Drug delivery into the vitreous chamber remains a great challenge in the pharmaceutical industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the mainstream route of drug administration to the posterior segment of the eye. The purpose of this review is to assess the current literature about the widening use of the intravitreal 0.7 mg dexamethasone (Dex) implant, and to provide a comprehensive collection of all the ocular disorders that benefit from Dex administration. Although anti-vascular endothelial growth-factors (VEGFs) have been largely indicated as a first-choice level, the Dex implant represents an important treatment option, especially in selected cases, such as vitrectomized eyes or patients in whom anti-VEGF failed or are contraindicated. In this article, the safety profile as well as the list of the possible complications related to intravitreal Dex injection are also discussed.

Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature / Iovino, Claudio; Mastropasqua, Rodolfo; Lupidi, Marco; Bacherini, Daniela; Pellegrini, Marco; Bernabei, Federico; Borrelli, Enrico; Sacconi, Riccardo; Carnevali, Adriano; D'Aloisio, Rossella; Cerquaglia, Alessio; Finocchio, Lucia; Govetto, Andrea; Erba, Stefano; Triolo, Giacinto; Di Zazzo, Antonio; Forlini, Matteo; Vagge, Aldo; Giannaccare, Giuseppe. - In: PHARMACEUTICS. - ISSN 1999-4923. - ELETTRONICO. - 12:(2020), pp. 703.1-703.26. [10.3390/pharmaceutics12080703]

Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature

Bacherini, Daniela;Finocchio, Lucia;
2020

Abstract

Drug delivery into the vitreous chamber remains a great challenge in the pharmaceutical industry due to the complex anatomy and physiology of the eye. Intravitreal injection is the mainstream route of drug administration to the posterior segment of the eye. The purpose of this review is to assess the current literature about the widening use of the intravitreal 0.7 mg dexamethasone (Dex) implant, and to provide a comprehensive collection of all the ocular disorders that benefit from Dex administration. Although anti-vascular endothelial growth-factors (VEGFs) have been largely indicated as a first-choice level, the Dex implant represents an important treatment option, especially in selected cases, such as vitrectomized eyes or patients in whom anti-VEGF failed or are contraindicated. In this article, the safety profile as well as the list of the possible complications related to intravitreal Dex injection are also discussed.
2020
12
1
26
Goal 3: Good health and well-being
Iovino, Claudio; Mastropasqua, Rodolfo; Lupidi, Marco; Bacherini, Daniela; Pellegrini, Marco; Bernabei, Federico; Borrelli, Enrico; Sacconi, Riccardo;...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1395751
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 35
  • ???jsp.display-item.citation.isi??? ND
social impact